REMD Biotherapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$994K
- Investors
-
4
REMD Biotherapeutics General Information
Description
Operator of a biopharmaceutical company intended to change and upgrade the practice of medicine. The company develops protein therapeutics to treat cancer, diabetes, and other diseases, enabling patients to have access to effective, safe, and affordable treatments.
Contact Information
Website
www.remdbio.comCorporate Office
- 4010 Adolfo Road
- Suite A
- Camarillo, CA 93012
- United States
Corporate Office
- 4010 Adolfo Road
- Suite A
- Camarillo, CA 93012
- United States
REMD Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 01-Sep-2020 | $994K | Completed | Clinical Trials - Phase 2 | ||
| 5. Grant | 16-Sep-2019 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 20-Nov-2017 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 27-Jul-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 01-Jul-2017 | $1.43M | Completed | Startup | ||
| 1. Grant | 01-Sep-2016 | $225K | Completed | Startup |
REMD Biotherapeutics Patents
REMD Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025178928-A1 | Combination therapy for the treatment of obesity | Pending | 23-Feb-2024 | ||
| WO-2025178928-A9 | Combination therapy for the treatment of obesity | Pending | 23-Feb-2024 | ||
| EP-4594363-A1 | C-c chemokine receptor type 8 (ccr8) antagonist antibodies | Pending | 02-Oct-2022 | ||
| EP-4594363-A4 | C-c chemokine receptor type 8 (ccr8) antagonist antibodies | Pending | 02-Oct-2022 | ||
| US-20260109770-A1 | C-c chemokine receptor type 8 (ccr8) antagonist antibodies | Pending | 02-Oct-2022 | C07K16/2866 |
REMD Biotherapeutics Signals
REMD Biotherapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases | Government | |||
| Jiuzhitang | Corporation | Minority | ||
| Shenzhen Naland Investment Fund Management | Growth/Expansion | Minority | ||
| U.S. Department of Health and Human Services | Government |
REMD Biotherapeutics FAQs
-
When was REMD Biotherapeutics founded?
REMD Biotherapeutics was founded in 2011.
-
Where is REMD Biotherapeutics headquartered?
REMD Biotherapeutics is headquartered in Camarillo, CA.
-
What is the size of REMD Biotherapeutics?
REMD Biotherapeutics has 8 total employees.
-
What industry is REMD Biotherapeutics in?
REMD Biotherapeutics’s primary industry is Drug Discovery.
-
Is REMD Biotherapeutics a private or public company?
REMD Biotherapeutics is a Private company.
-
What is REMD Biotherapeutics’s current revenue?
The current revenue for REMD Biotherapeutics is .
-
How much funding has REMD Biotherapeutics raised over time?
REMD Biotherapeutics has raised $30.1M.
-
Who are REMD Biotherapeutics’s investors?
National Institute of Diabetes and Digestive and Kidney Diseases, Jiuzhitang, Shenzhen Naland Investment Fund Management, and U.S. Department of Health and Human Services have invested in REMD Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process